Vor Biopharma (VOR) Operating Leases (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Operating Leases data on file, last reported at $2.6 million in Q1 2026.

• Quarterly Operating Leases fell 90.07% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (down 90.07% YoY) and the FY2025 annual result came in at $2.7 million, down 90.15% from the prior year.
• Operating Leases retreated to $2.6 million in Q1 2026 per VOR's latest filing, from $2.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $37.4 million in Q2 2022 and bottomed at $2.6 million in Q1 2026.
• The 5-year median for Operating Leases is $30.2 million (2024), against an average of $26.0 million.
• The widest annual swing landed in 2022, when Operating Leases soared 123.41%; it then sank 90.22% in 2025.
• Tracing VOR's Operating Leases over 5 years: stood at $35.6 million in 2022, then declined by 10.69% to $31.8 million in 2023, then dropped by 13.24% to $27.6 million in 2024, then slumped by 90.15% to $2.7 million in 2025, then slipped by 3.24% to $2.6 million in 2026.
• Per Business Quant, the three latest VOR Operating Leases figures stand at $2.6 million (Q1 2026), $2.7 million (Q4 2025), and $2.8 million (Q3 2025).

Peer Comparison